ABSTRACT
Patients with cystic fibrosis (CF) are a risk group for a severe course of respiratory viral diseases. In this regard, the European Cystic Fibrosis Society has developed the ECFS-COVID-19 surveillance program to collect information on the characteristics of COVID-19 in patients with cystic fibrosis, aimed at providing them with the necessary medical care. This article presents part of a study of Russian patients. Objective. To assess the prevalence and course of COVID-19 in Russian patients with CF and in the general Russian population. Materials and methods. From the beginning of the pandemic to December 31, 2020, 35 cases of COVID-19 in Russian children and adolescents with CF and 347,749 cases in the general population of children and adolescents were analyzed (findings from the Central Research Institute of Epidemiology of Rospotrebnadzor). Results. The proportion of children with COVID-19 in the Russian Federation was 11.3% of all reported cases, and the proportion of CF patients with COVID-19 - 10.1 per 1,000 pediatric CF patients. The main symptoms of COVID-19 in children with CF were fever, cough, rhinorrhea, abdominal pain syndrome, and no loss of smell. Most CF patients had asymptomatic or mild form of COVID-19, and hospitalization was more frequent compared to the general pediatric population. Conclusion. The study resulted in determination of prevalence of SARS-CoV-2 in CF patients and its clinical characteristics. Copyright © 2022, Dynasty Publishing House. All rights reserved.
ABSTRACT
Objective. To evaluate the efficacy of a benzydamine-containing drug in children with COVID-19. Patients and methods. This observational randomized study included 88 children with confirmed mild or moderate COVID-19. The experimental group comprised 44 children who received drugs containing benzydamine, whereas the control group comprised 44 children who received other local treatments. The groups were matched for age, sex, disease severity, main manifestations, and systemic therapy received. Results. Children in the experimental group demonstrated faster recovery than those from the control group (after 6.20 ± 2.93 days vs 7.36 ± 3.17 days, respectively;р < 0.05). Virus elimination occurred earlier in children receiving benzydamine than in controls (3.93 ± 2.48 days vs 5.27 ± 3.64 days, respectively;р < 0.05. Benzydamine significantly reduced the duration of pharyngeal hyperemia (by 2.29%), sore throat (by 1.77 days;р < 0.05), and fever (by 0.93 days;р < 0.05) compared to other local treatments. Conclusion. Benzydamine significantly increases the efficacy of COVID-19 treatment.
ABSTRACT
The article presents a clinical case of reactivation of chronic Epstein-Barr viral (EBV) infection complicated by the development of hepatitis in a 15-year-old teenager with COVID-19, which is of interest to infectious disease practitioners, pediatricians and other specialists in terms of the clinical course and differential diagnosis of these two viral diseases. It is shown that the reactivation of EBV against the background of the current new coronavirus infection COVID-19, accompanied by an increase in the level of aminotransferases in the blood, leads to a more severe course and prolonged stay of the patient in the hospital, as well as the appointment of additional drug therapy with subsequent rehabilitation measures.